Frazier Lifesciences Acquisition Corporation Stock
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.35 EUR | -8.01% | -2.83% | +68.85% |
Sales 2024 * | 8.61M 9.36M | Sales 2025 * | 6.3M 6.85M | Capitalization | 1.56B 1.7B |
---|---|---|---|---|---|
Net income 2024 * | -209M -227M | Net income 2025 * | -139M -151M | EV / Sales 2024 * | 181 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 248 x |
P/E ratio 2024 * |
-7.44
x | P/E ratio 2025 * |
-11.6
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Frazier Lifesciences Acquisition Corporation
1 day | -8.01% | ||
1 week | -2.83% | ||
Current month | +0.59% | ||
1 month | -13.57% | ||
3 months | -18.18% | ||
6 months | +93.04% | ||
Current year | +68.85% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 18.86 | -0.32% | 86 760 |
24-06-03 | 18.92 | +0.91% | 107,177 |
24-05-31 | 18.75 | +1.24% | 547,724 |
24-05-30 | 18.52 | -2.42% | 92,903 |
24-05-29 | 18.98 | -2.22% | 103,242 |
End-of-day quote Nasdaq, June 03, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.85% | 1.7B | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.95% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- NAMS Stock